Atritech

TriMed Staff | | Cardiovascular Business | Patient Care
Atritech (Booth 1424) is featuring its Watchman Left Atrial Appendage (LAA) closure technology, for which the FDA recently accepted its pre-market approval application based on the data of the PROTECT AF trial.  

The Watchman LAA system is designed to keep harmful sized blood clots that form in the left atrial appendage from entering your blood stream, potentially causing stroke or other complications. It is designed to be permanently placed just behind or at the opening of the left atrial appendage.

TriMed Staff

Related Content

Early pregnancy blood pressure patterns tied to hypertension risk years later
Enabling X-ray-free ablation procedures in the EP lab
Detecting coronary inflammation on CT imaging could reshape preventive cardiology
Know your options: What cardiologists recommend when alternative access is required for TAVR
New drug therapies targeting Lp(a) could be a breakthrough in cardiovascular care
Getinge ending production of cardiopulmonary surgical perfusion systems

Around the web

Radiology Business
The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.